Citizens Jmp Reaffirms "Market Perform" Rating for Cellectis (NASDAQ:CLLS)

Key Points

• Citizens JMP reaffirmed its “Market Perform” rating on Cellectis, while analyst opinions remain mixed; MarketBeat reports a consensus rating of “Moderate Buy” and an average price target of $7.00.
• Cellectis shares opened at $1.83, near their 12-month low of $1.75 and well below their 50-day and 200-day moving averages of $3.00 and $3.34, respectively.
• In its latest quarter, the biotechnology company reported an adjusted loss of $0.22 per share, beating estimates, but revenue of $6.90 million fell short of the $11.05 million consensus estimate.

Cellectis (NASDAQ:CLLS - Get Free Report)'s stock had its "market perform" rating reaffirmed by stock analysts at Citizens Jmp in a note issued to investors on Tuesday, Benzinga reports.

A number of other brokerages have also recently commented on CLLS. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Cellectis in a report on Friday, July 17th. Barclays began coverage on Cellectis in a report on Thursday, May 28th. They set an "overweight" rating and a $9.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Cellectis currently has an average rating of "Moderate Buy" and a consensus price target of $7.00.

Cellectis Stock Performance

Shares of CLLS opened at $1.83 on Tuesday. The company's 50 day simple moving average is $3.00 and its 200-day simple moving average is $3.34. The firm has a market cap of $183.62 million, a PE ratio of -2.82 and a beta of 2.92. Cellectis has a 12-month low of $1.75 and a 12-month high of $5.48. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 1.61.

Cellectis (NASDAQ:CLLS - Get Free Report) last released its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.04. Cellectis had a negative net margin of 102.34% and a negative return on equity of 94.19%. The firm had revenue of $6.90 million during the quarter, compared to the consensus estimate of $11.05 million.

Hedge Funds Weigh In On Cellectis

A hedge fund recently bought a new position in Cellectis stock. Lido Advisors LLC acquired a new position in shares of Cellectis S.A. (NASDAQ:CLLS - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 10,094 shares of the biotechnology company's stock, valued at approximately $32,000. Institutional investors own 63.90% of the company's stock.

About Cellectis

Cellectis SA NASDAQ: CLLS is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic T-cell therapies for cancer. The company uses its gene-editing technologies, including TALEN-based technology, to modify immune cells so they can be manufactured in advance and potentially administered to multiple patients rather than produced individually.

Cellectis' product candidates are designed primarily as chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and other serious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.